Cellphire Therapeutics Names Michael Gaffney as Company s New CEO
News provided by
Share this article
Share this article
ROCKVILLE, Md., April 20, 2021 /PRNewswire/ Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately. Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire. He will also join the Company s board. We re thrilled to have Mike join the Cellphire team, said Tom Dubin, Executive Chairman. He joins us at an exciting time, as Cellphire begins two Phase 2 clinical trials with two distinct investigational products, Thrombosomes® and Cryopreserved Platelets. Mike s proven and steady leadership and his background in health care and capital markets wil
Letter: Looking forward to reestablishing respectful, responsible dialogue post-election
Jan. 14, 2021
FacebookTwitterEmail
To the Editors:
Donald Trump’s baseless assertions regarding election results led directly to the assault on our nation’s Capitol building. The enabling Trumpist wing of the Republican party is equally to blame for the growing damage - together with Trump they continue to lie to the American public about election results, and then cite the concerns of the people that they misled as the basis for hijacking the electoral college process. Importantly, condemning the insurgents without condemning Trump and his enablers is a whitewash.
It is well-beyond time for all Americans to see Trump for what he is: a dangerous demagogue with no loyalties, no concern for truth, and no principles other than self-aggrandizement. A handful of responsible Republican leaders spoke with reason and perspective yesterday, both before and after the assault. Statements from the l